← Leaderboards
Parameswaran Ramakrishnan
Case Western Reserve University
$4,871,158
Attributed
$5,085,372
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $792.7K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,085,372 · 4
VA$0 · 1
By mechanism
R01$4,216,214 · 2
R21$869,158 · 2
I01$0 · 1
Top collaborators
- Reshmi Parameswaran2 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Wei Jiang$6,033,374
- Fabio Cominelli$30,550,057
- Luca Di Martino$610,350
- Ethan Honeycutt$98,512
- Adrian S Gomez-Nguyen$203,324
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsIn VivoGene ExpressionExperimental StudyMolecularGenesGenetic TranscriptionCellsTranscription FactorMouse ModelSerineCytokineSugarAffectChronicPost-Translational Protein ProcessingFutureMediatingPathologicChromatin ImmunoprecipitationImmuneBaseMolecular TargetFoundations
Grant awards (15)
Role of Sam68 in Proinflammatory Signaling$562,281
R01 · FY2025 · DK · contact PI
Targeting Hexosamine Biosynthetic Pathway and O-GlcNAcylation to Treat Acute Myeloid Leukemia$0
I01 · FY2025 · VA · contact PI
Targeting Hexosamine Biosynthetic Pathway and O-GlcNAcylation to Treat Acute Myeloid Leukemia$0
I01 · FY2025 · VA · contact PI
Role of Sam68 in Proinflammatory Signaling$543,870
R01 · FY2024 · DK · contact PI
Role of Sam68 in Proinflammatory Signaling$563,698
R01 · FY2023 · DK · contact PI
Role of Sam68 in Proinflammatory Signaling$565,115
R01 · FY2022 · DK · contact PI
Novel molecular agents targeting NF-κB c-Rel O-GlcNAcylation for the treatment of acute myeloid leukemia.$232,677
R21 · FY2021 · CA · contact PI
Transcriptional regulation by O-GlcNAcylation in T lymphocytes$396,250
R01 · FY2020 · AI · contact PI
Regulation of B cell function and antibody class switching by c-Rel O-GlcNAcylation$200,729
R21 · FY2020 · AI · contact PI
Novel molecular agents targeting NF-κB c-Rel O-GlcNAcylation for the treatment of acute myeloid leukemia.$195,752
R21 · FY2020 · CA · contact PI
Transcriptional regulation by O-GlcNAcylation in T lymphocytes$396,250
R01 · FY2019 · AI · contact PI
Regulation of B cell function and antibody class switching by c-Rel O-GlcNAcylation$240,000
R21 · FY2019 · AI · contact PI
Transcriptional regulation by O-GlcNAcylation in T lymphocytes$396,250
R01 · FY2018 · AI · contact PI
Transcriptional regulation by O-GlcNAcylation in T lymphocytes$396,250
R01 · FY2017 · AI · contact PI
Transcriptional regulation by O-GlcNAcylation in T lymphocytes$396,250
R01 · FY2016 · AI · contact PI